Last reviewed · How we verify

Misoprostol, per-oral tablets

Tampere University Hospital · FDA-approved active Small molecule

Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase gastric mucus production and reduce gastric acid secretion.

Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase gastric mucus production and reduce gastric acid secretion. Used for Prevention of NSAID-induced gastric ulcers, Treatment of gastric ulcers, Medical abortion (in combination with mifepristone).

At a glance

Generic nameMisoprostol, per-oral tablets
Also known asCytotec
SponsorTampere University Hospital
Drug classProstaglandin analogue
TargetProstaglandin E1 receptor (EP receptor)
ModalitySmall molecule
Therapeutic areaGastroenterology; Obstetrics
PhaseFDA-approved

Mechanism of action

Misoprostol acts as a synthetic prostaglandin analogue that activates EP3 and other prostaglandin receptors on gastric mucosa. This stimulates mucus and bicarbonate secretion while simultaneously reducing gastric acid production, thereby protecting the gastric lining. It is commonly used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers and is also employed for cervical ripening and labor induction due to its uterotonic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: